Actively Recruiting
Open-label Multi-center Study of IEV407 Alone or with Endocrine Therapy in Advanced HRHER2- Breast Cancer
Led by Novartis Pharmaceuticals · Updated on 2026-11-03
194
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and early effects of a new drug called IEV407, both alone and combined with endocrine therapies fulvestrant or letrozole, in people with advanced hormone receptor positive HR, HER2-negative breast cancer. This is a first-in-human, open-label phase IIb study that includes a dose escalation phase followed by a dose expansion phase to find optimal dosing and assess combination treatments. The study begins with testing IEV407 alone to find the right dose. After that, combinations of IEV407 with fulvestrant or letrozole will be studied. The dose expansion phase may involve random assignment to different treatment groups if more than one option is available simultaneously. Treatments involve oral IEV407 and endocrine therapies delivered either orally or by injection, depending on the drug. Participants will be monitored for safety through assessments of side effects, laboratory tests, and dose adjustments over up to about two years. Researchers will measure toxicities, treatment interruptions, and drug levels in the blood. They will also evaluate cancer responses and progression. The study includes regular visits and evaluations to track how participants respond to the treatments over time.
CONDITIONS
Brief Title
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here